Drug Reimbursement: FDA Approves Two New Cancer Drugs

Why This Topic Matters

Newly approved drugs can affect claim coding, payer coverage, and documentation requirements quickly. This article helps readers identify the relevant billing, diagnosis, and administration considerations tied to these cancer therapies.

Article Sections

1. Billing and documentation for the new cancer drugs

   Introduces the reimbursement topic and the general billing and documentation considerations associated with the newly approved oncology drugs.

2. Chemotherapy administration and payer coverage notes

   Summarizes the related administration services and mentions payer-specific coverage and pricing information relevant to the drugs.

3. Diagnosis coding and manufacturer support resources

   Covers the diagnosis coding categories referenced for coverage support and points to a manufacturer resource for obtaining coding and enrollment assistance.